For the quarter ending 2025-09-30, BBIO made $120,700K in revenue. -$182,743K in net income. Net profit margin of -151.40%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues, net | 120,700 | 110,565 | 73,057 | 2,732 |
| Cost Of License Services And Royalty Revenue | - | 805 | - | - |
| Product | 4,028 | - | - | - |
| Cost Of Goods Sold | - | 2,848 | - | - |
| License Services And Royalty | 2,535 | - | - | - |
| Restructuring, impairment and related charges | - | - | 3,661 | 4,621 |
| Total cost of revenues | 6,563 | 3,653 | 1,093 | 598 |
| Research and development | 112,874 | 111,231 | 128,672 | 120,444 |
| Selling, general and administrative | 137,621 | 129,154 | 73,371 | 68,819 |
| Restructuring, impairment and related charges | 8,841 | 805 | - | - |
| Total operating costs and expenses | 265,899 | 244,843 | 206,798 | 194,482 |
| Loss from operations | -145,199 | -134,278 | -133,741 | -191,750 |
| Interest income | 6,239 | 3,898 | 2,435 | 3,296 |
| Interest expense | 11,739 | 37,637 | 25,410 | 23,061 |
| Noncash interest expense on deferred royalty obligations | 36,410 | - | - | - |
| Gain on deconsolidation of subsidiaries | 0 | 0 | 42,098 | 52,027 |
| Loss on extinguishments of debt | 0 | 0 | -6,647 | - |
| Net loss from equity method investments | -15,834 | -20,189 | -8,207 | -6,563 |
| Other income, net | 16,461 | 6,548 | 3,492 | 1,797 |
| Total other income (expense), net | -41,283 | -47,380 | 7,761 | 27,496 |
| Loss before income taxes | -186,482 | -181,658 | -135,548 | - |
| Provision for (benefit from) income taxes | -1,545 | 2,100 | 9,761 | - |
| Net loss | -184,937 | -183,758 | -126,364 | -164,254 |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | -2,194 | -1,855 | -1,790 | -2,214 |
| Net loss attributable to common stockholders of bridgebio | -182,743 | -181,903 | -124,574 | -162,040 |
| Net loss per share attributable to common stockholders of bridgebio, basic (in dollars per share) | -0.95 | -0.95 | -0.673 | -0.86 |
| Net loss per share attributable to common stockholders of bridgebio, diluted (in dollars per share) | -0.95 | -0.95 | -0.673 | -0.86 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of bridgebio, basic (in shares) | 191,854,152 | 190,517,215 | -811,499.667 | 188,510,372 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of bridgebio, diluted (in shares) | 191,854,152 | 190,517,215 | -811,499.667 | 188,510,372 |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)